UroGen Pharma (URGN) Return on Equity [ROE] (2017 - 2024)
UroGen Pharma's Return on Equity [ROE] was -1518.36% in Q4 2024, down 1105.03 percentage points from the prior quarter.
Powered by 
Analysis
UroGen Pharma (URGN) Return on Equity [ROE] (2017 - 2024) Analysis & Trends
For FY2021, Return on Equity [ROE] at UroGen Pharma came in at -211.55%, down 118.67 percentage points from FY2020.
- Return on Equity [ROE] shows a five-year change of -199.64 percentage points (FY2016 to FY2021).
- In earlier years, Return on Equity [ROE] was -92.88% in FY2020 (-15.11 pp), -77.77% in FY2019 (+17.63 pp), -95.40% in FY2018 (-48.24 pp) and -47.16% in FY2017 (-35.25 pp).
- The Q4 2024 figure marks the lowest quarterly Return on Equity [ROE] in data going back to Q4 2017.
- The year-over-year drop in Return on Equity [ROE] has ranged between 23.80 percentage points (Q1 2020) and 435.60 percentage points (Q4 2021) over the last five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | UroGen Pharma | 2.02 Bn | 1.53 Bn | 65.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -1,518.36% |
| Sep 30, 2024 | -413.33% |
| Dec 31, 2021 | -554.79% |
| Sep 30, 2021 | -257.14% |
| Jun 30, 2021 | -167.97% |
| Mar 31, 2021 | -134.95% |
| Dec 31, 2020 | -119.19% |
| Sep 30, 2020 | -105.30% |
| Jun 30, 2020 | -90.89% |
| Mar 31, 2020 | -75.95% |
| Dec 31, 2019 | -55.97% |
| Sep 30, 2019 | -42.99% |
| Jun 30, 2019 | -39.32% |
| Mar 31, 2019 | -52.15% |
| Dec 31, 2018 | -79.33% |
| Sep 30, 2018 | -57.99% |
| Jun 30, 2018 | -35.53% |
| Mar 31, 2018 | -30.87% |
| Dec 31, 2017 | -27.39% |
API Access
UroGen Pharma Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=URGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "URGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=URGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();